A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Participants aged between 18 and 75 years at enrolment.
Participants with history or presence of at least two components of metabolic syndrome.
Liver biopsy consistent with cirrhosis (fibrosis stage 4).
You may not be if
Participants with other chronic liver diseases.
Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma.
Participants with history of Type 1 diabetes mellitus; or major Type 2 diabetes mellitus complications.
History or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before Screening.
A recent history or planned surgical procedures or medications intended to produce significant weight loss.
Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>= 5 times upper limit normal (ULN).
Current or history of excessive alcohol intake
Clareo Health | A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
